ACRS: Aclaris Therapeutics Inc
ACRS exchange rate has changed by -1.92% for today. During the day, the instrument was traded at a low of 3.00 and at a high of 3.13.
Follow Aclaris Therapeutics Inc dynamics. Real-time quotes will help you quickly react to market changes. By switching between different timeframes, you can monitor exchange rate trends and dynamics by minutes, hours, days, weeks, and months. Use this information to forecast market changes and to make informed trading decisions.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
ACRS News
- Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline
- Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates
- Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates
- Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
- Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates
- Aclaris starts phase 1b trial of ATI-052 in asthma patients
- Craig-Hallum initiates coverage on Aclaris Therapeutics stock with Buy rating
- Aclaris stock gets Buy rating reaffirmed by H.C. Wainwright after positive preclinical results
- Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug - Aclaris Therapeutics (NASDAQ:ACRS)
- Aclaris reports positive preclinical results for hair loss drug
- U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.76%
- Aclaris begins phase 1b trial of ATI-052 for atopic dermatitis
- Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target
- Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages - Slideshow (NASDAQ:ACRS) 2026-01-06
- Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript
- Aclaris reports positive results for anti-inflammatory drug ATI-052
- Applovin, Oracle among market cap stock movers on Tuesday
Frequently Asked Questions
What is ACRS stock price today?
Aclaris Therapeutics Inc stock is priced at 3.06 today. It trades within 3.00 - 3.13, yesterday's close was 3.12, and trading volume reached 1529. The live price chart of ACRS shows these updates.
Does Aclaris Therapeutics Inc stock pay dividends?
Aclaris Therapeutics Inc is currently valued at 3.06. Dividend policy depends on the company, while investors also watch 100.00% and USD. View the chart live to track ACRS movements.
How to buy ACRS stock?
You can buy Aclaris Therapeutics Inc shares at the current price of 3.06. Orders are usually placed near 3.06 or 3.36, while 1529 and 1.32% show market activity. Follow ACRS updates on the live chart today.
How to invest into ACRS stock?
Investing in Aclaris Therapeutics Inc involves considering the yearly range 1.05 - 4.89 and current price 3.06. Many compare 8.13% and 61.90% before placing orders at 3.06 or 3.36. Explore the ACRS price chart live with daily changes.
What are Aclaris Therapeutics Inc stock highest prices?
The highest price of Aclaris Therapeutics Inc in the past year was 4.89. Within 1.05 - 4.89, the stock fluctuated notably, and comparing with 3.12 helps spot resistance levels. Track Aclaris Therapeutics Inc performance using the live chart.
What are Aclaris Therapeutics Inc stock lowest prices?
The lowest price of Aclaris Therapeutics Inc (ACRS) over the year was 1.05. Comparing it with the current 3.06 and 1.05 - 4.89 shows potential long-term entry points. Watch ACRS moves on the chart live for more details.
When did ACRS stock split?
Aclaris Therapeutics Inc has gone through stock splits historically. These changes are visible in , 3.12, and 100.00% after corporate actions.
- Previous Close
- 3.12
- Open
- 3.02
- Bid
- 3.06
- Ask
- 3.36
- Low
- 3.00
- High
- 3.13
- Volume
- 1.529 K
- Daily Change
- -1.92%
- Month Change
- 8.13%
- 6 Months Change
- 61.90%
- Year Change
- 100.00%